CG Oncology (CGON) Price/OCF Ratio: History & Chart

CG Oncology Inc.(CGON)

Biotechnology · Dallas, TX

$65.42-3.29 (-4.79%)

Delayed quote: Oct 6, 2026, 11:00 AM EDT

About CG Oncology Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Dallas, TX

142 employees

cgoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur Kuan

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
CG Oncology Inc. (CGON)	$5.77B	N/A	N/A	N/A	N/A
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.70B	30.77	31.51	57.31	58.06
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.84B	N/A	1.10	1.10	1.10
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.95B	45.19	80.09	48.34	34.61
MiniMed Group, Inc. Common Stock (MMED)vs ›	$5.54B	N/A	N/A	N/A	N/A
GRAIL Inc. (GRAL)vs ›	$6.03B	N/A	N/A	N/A	N/A
Doximity, Inc. (DOCS)vs ›	$5.35B	17.48	20.94	34.29	45.54
CRISPR Therapeutics AG (CRSP)vs ›	$5.27B	N/A	11.41	54.55	54.55
Cogent Biosciences, Inc. (COGT)vs ›	$5.24B	N/A	N/A	N/A	N/A
Scholar Rock Holding Corporation (SRRK)vs ›	$5.12B	N/A	27.45	27.45	27.45

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

CG Oncology Inc. (CGON)

$5.77B

N/A

Kiniksa Pharmaceuticals International, plc (KNSA)vs ›

$5.70B

30.77

31.51

57.31

58.06

Iovance Biotherapeutics, Inc. (IOVA)vs ›

$5.84B

N/A

1.10

Ligand Pharmaceuticals Incorporated (LGND)vs ›

$5.95B

45.19

80.09

48.34

34.61

MiniMed Group, Inc. Common Stock (MMED)vs ›

$5.54B

N/A

GRAIL Inc. (GRAL)vs ›

$6.03B

N/A

Doximity, Inc. (DOCS)vs ›

$5.35B

17.48

20.94

34.29

45.54

CRISPR Therapeutics AG (CRSP)vs ›

$5.27B

N/A

11.41

54.55

Cogent Biosciences, Inc. (COGT)vs ›

$5.24B

N/A

Scholar Rock Holding Corporation (SRRK)vs ›

$5.12B

N/A

27.45

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

CGON Price/OCF Ratio Metrics

CGON Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics